AnaptysBio, Inc. (ANAB)
| Market Cap | 1.52B +145.0% |
| Revenue (ttm) | 106.09M -13.9% |
| Net Income | 261.99M |
| EPS | 7.00 |
| Shares Out | 29.90M |
| PE Ratio | 7.26 |
| Forward PE | 14.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 412,660 |
| Open | 51.00 |
| Previous Close | 51.00 |
| Day's Range | 50.50 - 51.65 |
| 52-Week Range | 23.15 - 73.30 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 88.50 (+74.21%) |
| Earnings Date | Sep 21, 2026 |
About ANAB
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclus... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ANAB stock is "Strong Buy." The 12-month stock price target is $88.5, which is an increase of 74.21% from the latest price.
News
AnaptysBio price target lowered to $81 from $90 at Leerink
Leerink lowered the firm’s price target on AnaptysBio (ANAB) to $81 from $90 and keeps an Outperform rating on the shares. The firm notes the company reported June quarter results…
AnaptysBio reports Q2 diluted EPS $5.11 vs. ($1.30) last year
Reports Q2 revenue $27.5M, consensus $20.12M. Cash, cash equivalents and investments totaled $164.1M as of June 30, compared to $211.6M as of December 31, 2025, for a decrease of $47.5M…
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidol...
AnaptysBio Earnings release: Q2 2026
AnaptysBio released its Q2 2026 earnings on September 21, 2026, summarizing the period's financial results.
AnaptysBio Slides: Corporate presentation
AnaptysBio has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
AnaptysBio Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Following a strategic spin-out, the company now operates virtually, focusing on maximizing shareholder value through tiered royalties from JEMPERLI and a potential second stream from imsidolimab. Key catalysts include litigation resolution, regulatory milestones for JEMPERLI and imsidolimab, and a share repurchase plan.
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announ...
AnaptysBio price target lowered to $70 from $75 at TD Cowen
TD Cowen lowered the firm’s price target on AnaptysBio (ANAB) to $70 from $75 and keeps a Buy rating on the shares. The firm updated its model after GSK (GSK)…
AnaptysBio falls -10.8%
AnaptysBio (ANAB) is down -10.8%, or -$6.75 to $55.76.
AnaptysBio Proxy statement: Proxy filing
AnaptysBio filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
AnaptysBio Proxy statement: Proxy filing
AnaptysBio filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
AnaptysBio assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of AnaptysBio (ANAB) with a Buy rating and $95 price target The company is now focused on its royalty-bearing assets, the analyst tells investors in a…
AnaptysBio price target raised to $90 from $85 at Leerink
Leerink raised the firm’s price target on AnaptysBio (ANAB) to $90 from $85 and keeps an Outperform rating on the shares. Although Q1 Jemperli collaboration revenue was below expectations, the…
AnaptysBio price target raised to $76 from $60 at UBS
UBS raised the firm’s price target on AnaptysBio (ANAB) to $76 from $60 and keeps a Buy rating on the shares.
AnaptysBio price target raised to $75 from $63 at Barclays
Barclays raised the firm’s price target on AnaptysBio (ANAB) to $75 from $63 and keeps an Overweight rating on the shares following the Q1 report. The company continues to execute…
AnaptysBio reports Q1 EPS ($1.84), consensus (75c)
Reports Q1 revenue $25.56M, consensus $18.87M. “Following the completion of the spin-off of First Tracks Bio in late April, Anaptys now exclusively manages the financial collaborations for Jemperli an...
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported...
AnaptysBio Earnings release: Q1 2026
AnaptysBio released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
AnaptysBio Quarterly report: Q1 2026
AnaptysBio has published its Q1 2026 quarterly earnings report on May 12, 2026.
AnaptysBio appoints Christopher Murphy as CFO
AnaptysBio (ANAB) announced the appointment of Christopher Murphy as CFO and Owen Hughes as a member of its board of directors. Murphy previously served as CFO and CBO of Third…
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announce...
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announce...
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
Piper Sandler lowered the firm’s price target on AnaptysBio (ANAB) to $93 from $95 and keeps an Overweight rating on the shares. The firm notes that on April 2026, AnaptysBio…
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...
AnaptysBio price target raised to $85 from $66 at Leerink
Leerink raised the firm’s price target on AnaptysBio (ANAB) to $85 from $66 and keeps an Outperform rating on the shares.